Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous TransplantGlobeNewsWire • 06/27/22
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?Zacks Investment Research • 06/20/22
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/22
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual MeetingGlobeNewsWire • 05/02/22
Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease ConferenceGlobeNewsWire • 03/25/22
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare ConferenceGlobeNewsWire • 03/08/22
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/28/22
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/09/22
Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene TherapySeeking Alpha • 01/19/22
Pfizer announces deal worth up to $1.3 billion with Beam; Beam's stock is up 4.9%Market Watch • 01/10/22
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing ProgramsBenzinga • 01/10/22
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare DiseasesBusiness Wire • 01/10/22